404 related articles for article (PubMed ID: 32585295)
1. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
2. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
4. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
5. Covid-19: Time for a paradigm change.
Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
[No Abstract] [Full Text] [Related]
6. A plea for the pathogenic role of immune complexes in severe Covid-19.
Vuitton DA; Vuitton L; Seillès E; Galanaud P
Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
[No Abstract] [Full Text] [Related]
7. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
8. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.
Ahlawat S; Asha ; Sharma KK
Virus Res; 2020 Sep; 286():198103. PubMed ID: 32717345
[TBL] [Abstract][Full Text] [Related]
9. Treating COVID-19 with colchicine in community healthcare setting.
Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
[No Abstract] [Full Text] [Related]
10. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.
Ratajczak MZ; Kucia M
Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300
[TBL] [Abstract][Full Text] [Related]
12. How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?
Kloc M; Ghobrial RM; Kubiak JZ
Immunol Lett; 2020 Aug; 224():28-29. PubMed ID: 32522666
[TBL] [Abstract][Full Text] [Related]
13. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
14. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
15. The type I interferon response in COVID-19: implications for treatment.
Lee JS; Shin EC
Nat Rev Immunol; 2020 Oct; 20(10):585-586. PubMed ID: 32788708
[TBL] [Abstract][Full Text] [Related]
16. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
17. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
18. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
Chrousos GP; Meduri GU
Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
[No Abstract] [Full Text] [Related]
19. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
20. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
Theoharides TC
Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
[No Abstract] [Full Text] [Related]
[Next] [New Search]